In a couple of years Anavex will have sales of Blarcamesine.
It is estimated that there are approximately 44 million people worldwide living with Alzheimer's disease or a related form of dementia. In the U.S., an estimated 5.5 million people of all ages have Alzheimer's disease.
If we estimate that in couple of years 10% of Alzheimer’s patients start taking Blarcamesine each and every day at a price of say $10.00 per day, then 4,400,000 patients at $10.00 per day would be sales starting at 308 million per week. That would be $16 billion per year. With a conservative profit margin of just 50% that would be $8 billion in profit/earnings. $8,000,000,000 divided by an estimate of 100,000,000 shares would be a profit/earnings of $80.00 per share. With a conservative PE ratio of just 20, then that would equate to conservatively $1600 per share for AVXL.
Good luck and GOD bless,
Market Data 
Markets 
AI
